BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions
路透社2026/10/07 14:16October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)
October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87
** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash
** The company obtained this voucher after the FDA approved its drug Genglycos (link) for the treatment of type Ia glycogen storage disease (also known as Von Gierke disease)
** According to the licensing agreement, after the deal is completed, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health
** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet responded
** The recommended retail price of Genglycos in the United States is $2.7 million per patient
** As of the close of the previous trading day, the stock had fallen about 35% year to date
(To support non-native English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or lack necessary context, and Reuters does not guarantee the accuracy of the translated text. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss caused by the use of its automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Third Life World signs deal to buy voting control of Transglobal Management Group
Third Life World signed a definitive control share purchase agreement to take voting control of Transglobal Management Group (TMGI). The deal transfers a Series A Preferred control block holding a majority of voting rights to Third Life World. TMGI plans to make Third Life World’s AI-agent virtual world platform its core operating business. TMGI will create new Series B Preferred Stock to support the purchase; closing remains subject to customary conditions. At closing, controlling shareholder Marc Angell will resign his officer roles and stay on as a consultant during the transition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transglobal Management Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081100PRIMZONEFULLFEED9842281) on October 08, 2026, and is solely responsible for the information contained therein.
Active Measures To Increase XRP Price. Here’s the Latest
STRK breaks through 0.06 USDT, up more than 25% in 24 hours
BUZZ-CSL plans to convert all its plasma centers in the US to use Haemonetics equipment, driving the company's stock price to soar
October 8 – ** Shares of medical device manufacturer Haemonetics (HAE.N) surged nearly 16% to $117.81 ** The stock hit an intraday high of $120.61, marking its highest level since early 2021 ** The company stated that CSL Plasma, a subsidiary of Australia’s CSL Group (CSL.AX), expects to transition all its U.S. plasma collection centers to using HAE’s NexSys devices and kits by the end of 2027 ** CSL has also terminated its agreement with HAE rival Terumo (Terumo 4543.T) – according to BTIG ** This transition will help HAE win back business lost since 2021, when its largest plasma client CSL announced it would not renew its U.S. supply contract ** BTIG estimates that, based on approximately $155 million in revenue HAE generated from CSL’s U.S. business in fiscal year 2024, this account could add about $0.60 per share to adjusted earnings annually, though it notes that actual revenue and profit margins remain unclear ** The brokerage maintained its “Buy” rating and raised its price target from $110 to $130, stating that the deal alleviates market share loss concerns and boosts sales growth prospects ** Including today’s gains, the stock is up 49.46% so far this year (For the convenience of non-English speakers, Reuters provides its reports in several other languages through automated translation. Because automated translation may be inaccurate or lack needed context, Reuters does not guarantee the accuracy of the automated text, which is offered purely as a reader service. Reuters accepts no liability for any damage or loss caused by the use of automated translation services.)
Crypto prices
More
